It’s a new name, new game energy, as music company Vinyl (ASX: VNL)—formerly Jaxsta—acquires entertainment giant The Brag Media, the Australian publisher of Variety magazine and Rolling Stone AU/NZ. Vinyl will fully acquire the publisher, including its premium network of mastheads and events funded by a new investment by WiseTech Global (ASX: WTC) Founder and
Read More
The XJO is expected to open lower this morning following a strong pullback in the U.S overnight. Their futures are flat. The inevitable pullback happened last night in no uncertain terms. It is hard to suggest this is the result of anything serious or a genuine change in trend, but rather some well overdue profit
Read More
In Chile, one in eight adults have diabetes. The number of people with the condition there has risen almost 50% in the past ten years. By 2030, the healthcare spending on diabetes in Chile is set to surpass $4 billion. Chile’s healthcare needs demand companies like medical tech company Proteomics (ASX: PIQ) that emphasise early
Read More
The first four months of FY24 have not been kind on clothing retailer KMD Brands (ASX: KMD), the Group behind the ubiquitous winterwear retailer Kathmandu (spotting Kathmandu jackets during Aussie winters could very well be a drinking game). However, with winters having passed, KMD has reported a 12.5% decline in group sales compared to the
Read More
The XJO is expected to open higher this morning following another night of gains in the U.S. Their futures are flat. Yesterday we managed to break through key resistance at roughly 7,450 and today we look set to test the next key level at roughly 7,550. The strength underpinning markets is almost dizzying and it
Read More
In a significant move signalling strong confidence in Syntara (ASX: SNT) and their drugs in development, institutional investors have subscribed for $10 million of shares, driven by the immediate commercial prospects of their leading drug SNT-5505. The funds will also support an emerging pipeline of drugs addressing Parkinson’s disease and skin scar trials. The $10m
Read More